Table 1.
Baseline characteristics of patients in study
| Entire cohort | Genotype–phenotype cohort | |
|---|---|---|
| Characteristics | (N=176) | (N=134)a |
| Age (years), mean (range) | 55 (32–82) | 50 (33–78) |
| Premenopausal | 49 (32–63) | 48 (34–63) |
| Perimenopausal | 53 (45–60) | 63 (39–80) |
| Postmenopausal | 64 (39–82) | |
| BMI, mean (SD) | 27 (8) | 27 (6) |
| Race/ethnicityb | ||
| African Americans | 8 (4)c | 7 (5) |
| Caucasians | 161 (92) | 125 (93) |
| Othersc | 7 (4) | 3 (2) |
| Menopausal statusb | ||
| Premenopausal | 55 (31) | 53 (39) |
| Perimenopausal | 20 (11) | 0 (0) |
| Postmenopausal | 101 (57) | 81 (61) |
| Patients on lipid-lowering medications b | ||
| At baseline | 22 | 0 |
| At 4 months | 22 | 0 |
BMI, base metabolic index; N, number in each category.
a
Genotype–phenotype cohort refers to the 136 patients for the genotype–lipid association analysis who were neither perimenopausal nor on lipid-lowering medications.
b
Number in group (%).
c
Others consist of two patients of Arabic, one of Hispanic, one of Asian, and two of unknown ancestry, and race/ethnicity percentages may not add up to 100 because of rounding.